Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 21:7:212549.
doi: 10.7573/dic.212549. eCollection 2018.

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Muhammad Saad  1 , Umut Gomceli  2 , Pranav Ravi  1 , Andrisael G Lacoste  1 , Neil Shah  1 , Timothy J Vittorio  2
Affiliations
Review

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Muhammad Saad et al. Drugs Context. .

Abstract

Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HF-related complications. In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the T2DM population. This article will help the reviewer to comprehend the pathophysiology of HF and the potential role of SGLT-2 inhibitors in the management algorithm of HF and its associated risk factors in T2DM.

Keywords: SGLT-2 inhibitors; heart failure.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/10/dic.212549-COI.pdf

Figures

Figure 1
Figure 1
SGLT-2 interaction with cardiac and renovascular system.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College Of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. http://dx.doi.org/10.1016/j.jacc.2013.05.019 - DOI - PubMed
    1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the esc. Eur J Heart Failure. 2012;14(8):803–869. http://dx.doi.org/10.1093/eurjhf/hfs105 - DOI - PubMed
    1. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1–194. http://dx.doi.org/10.1016/j.cardfail.2010.04.004 - DOI - PubMed
    1. Bianucci R, Loynes RD, Sutherland ML, et al. Forensic analysis reveals acute decompensation of chronic heart failure in a 3500-year-old Egyptian dignitary. J Forensic Sci. 2016;61(5):1378–1381. http://dx.doi.org/10.1111/1556-4029.13138 - DOI - PubMed
    1. Davis RC, Hobbs FD, Lip GY. ABC of heart failure. History and epidemiology. BMJ. 2000;320(7226):39–42. - PMC - PubMed